The effect of Curcumex on Type 2 diabetic patients

The effect of Curcumex on fasting plasma glucose, HbA1c, Lipid profile, Insulin resistance and Inflammatory biomarkers in patients with type 2 diabetes mellitus: A randomized double blind clinical Trial.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181028041483N1

Enrollment

Registered

2019-01-16

Start date

2018-11-22

Completion date

Unknown

Last updated

2019-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes mellitus type 2.

Interventions

Intervention 1: Intervention group: Curcumex 2 times a day for 3 months. Intervention 2: Control group: Placebo ,2 times a day for 3 months.

Eligibility

Sex/Gender

All

Age

30 Years to 80 Years

Inclusion criteria

Inclusion criteria: Baseline A1c <9% Fasting blood glucose is between 200-126 mg / dl Patients only use oral hypoglycemic drugs Duration of diagnosis of diabetes is less than 10 years

Exclusion criteria

Exclusion criteria: Pregnancy and lactation Insulin treatment Sensitization and allergy to black pepper or other ingredients in combination Significant renal and hepatic failure

Design outcomes

Primary

Measure	Time frame
The percentage of people who have fasting blood glucose (200-126 mg / dL). Timepoint: Before the intervention begins and Day 90. Method of measurement: Parsazmoon's FBS kit.;The percentage of people who have glycosylated hemoglobin (9% -7%). Timepoint: Before the intervention begins and Day 90. Method of measurement: Diazyme's HbA1c kit.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Asghar Hemmati

Ahvaz University of Medical Sciences

Hemmati-aa@ajums.ac.ir+98 61 3373 8382

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026